Abstract 780P
Background
In high-grade ovarian cancer (OC) TCGA found BRCA1meth inferior to BRCAmut regarding prognosis probably due to lower sensitivity to platinum (Pt++)-based chemotherapy.
Methods
In 143 high-grade OCs tested for BRCA mutations, additionally BRCA DNA methylation was determined using MethyLight PCR and genome-wide LOH and Aneuploidy Normalized Telemetric imbalance (ANTI) by means of SNP-Array analysis (GSA-24 v 3.0/Illumina) as surrogates of genome-wide DNA-scarring. For LOH and ANTI a “clinical-threshold” was calculated by Pt++-response, determined at the first recurrence. Both were integrated in a common HRD-Score (cut-off: ≥1.912 for HRD positivity).
Results
In the present cohort, BRCA1 DNA methylation (meBRCA1) was detected in 15 (10%) and mostly BRCAwt OCs (n=14, 17%). Only one BRCA1mut OC had concomitant meBRCA1. BRCA2 DNA methylation was not observed. In terms of genomic scars, meBRCAwt and BRCAmut OCs had similar HRD scores, which were higher than those in unmethylated BRCAwt OCs (p<0.003). In BRCAwt OCs, BRCA1 methylation levels (PMR-values) were higher in HRD pos. than in HRD negative OCs (p<0.001). Progression free survival (PFS) of patients with meBRCA1 OCs was noninferior to that of BRCAmut OC patients. Worst PFS and OS was found in the subgroup of unmethylated BRCAwt OCs compared to patients with BRCAmut and meBRCA1 OCs in univariate (p=0.003; p=0.022) and multivariate survival analysis (p=0.006, p=0.018). All but one of the cancers classified as Pt++-refractory or -resistant at first relapse (92%) were unmethylated BRCAwt OCs. None of the meBRCA1 cancers were rated Pt++-refractory or -resistant, and only one BRCAmut OCs was associated with a Pt++-resistant first relapse. 98.6% of the recurrences originating from OCs with genetically or epigenetically altered BRCA genes were Pt++-sensitive, of which 77% were considered highly sensitive.
Conclusions
High-grade OCs without genetic or epigenetic BRCA alterations exhibit worst PFS. Based on genome-wide scarring, BRCA1 promotor methylation seems to exert an equivalent detrimental effect on the DNA repair by homologous recombination as pathogenic BRCA mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
790P - Uniform prospective molecular analysis of endometrial carcinoma: Feasibility, outcomes, and effect on management
Presenter: Bradley Corr
Session: Poster session 11
791P - Development and validation of nomograms to predict survival in patients with high-grade serous ovarian cancer
Presenter: Xiaolian Peng
Session: Poster session 11
792P - Prognostic role of the modeled CA-125 KELIM in early FIGO stage I and II ovarian cancers (OC): A GCIG individual-patient data meta-analysis
Presenter: Pauline Corbaux
Session: Poster session 11
793P - Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)
Presenter: Ana Maria Catana
Session: Poster session 11
794P - Efficacy of gemcitabine (gem) based therapy in ovarian clear cell carcinoma (OCCC)
Presenter: Jerold Loh
Session: Poster session 11
795P - Tolerability and effectiveness of niraparib in long-term responders with platinum-sensitive recurrent ovarian cancer (GEICO-88R study)
Presenter: Juan Cueva Banuelos
Session: Poster session 11
796P - Initial management and long-term outcome of advanced low-grade serous ovarian cancer (LGSOC) exploring role of surgery and maintenance therapy in the French multicentre ESME database
Presenter: Thomas Papazyan
Session: Poster session 11
797P - Impact of consolidation cycles in predicting recurrence in patients treated with EMA-CO for high-risk gestational trophoblastic neoplasia
Presenter: Antoine DELEUZE
Session: Poster session 11
798P - Survival analysis of non-metastatic gestational choriocarcinoma (NMGCC) patients treated with chemotherapy
Presenter: Sakhr Alshwayyat
Session: Poster session 11